Artificial Intelligence
in Pharma and Healthcare
Drug development, flawless legal documents, and faster diagnoses
Use Cases
The healthcare and pharmaceutical industry benefits in countless areas through the use of artificial intelligence.
For example, AI can simulate the chemical interactions used to evaluate a drug’s efficacy. This allows for quick and accurate identification of vaccines against viral infections.
AI can evaluate medical records, understand potential interventions based on specific criteria, and fully automate review processes, eliminating many overhead and repetitive tasks.
Benefits of AI
The global healthcare AI market size was estimated at $15.1 billion in 2022 and is expected to reach nearly $188 billion by 2030, growing at an impressive CAGR of 37% during the forecast period 2022 to 2030.
In contrast, estimates for the global AI market in the pharmaceutical sector are much lower. In 2022, it was estimated at $1,170.28 million. It is expected to level off at $9,241.34 million by 2030, at a CAGR of 29.5%.
AI applications can make a big difference in the healthcare and pharma industry
More Information
We have been serving leading companies in the pharmaceutical and healthcare industry for many years. All of them deal with the topic of AI.
Therefore, we have compiled a booklet with interesting use cases, benefits, and market data for you, which you can download here for free.
Download
One click is missing to download…
We have sent you an e-mail for data protection reasons.
Please open this e-mail in your mailbox
Click on the link in our email to confirm your email address. We will then provide you with the link on our site.
Thank you for your interest. The download will start automatically.
If not, please click on the following link.
Are you interested in exchanging ideas on this topic?
Then contact us at experts@striped-giraffe.com.
WE CREATE ADDED VALUE FOR OUR CUSTOMERS.
This leads to a long-term cooperation with our customers, which we appreciate very much. You can find even more e-books, case studies, and co. in our Insights.
